精准医疗：现在和未来 | 2024 BioSpark年会

 汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

What will we talk about?

• Oncology Precision Medicine - Where are we now? Lessons learned during the cancer genomics era

• Moving beyond TCGA - emerging technologies, approaches, and  new modalities

• Immuno-oncology - perspectives from biotech and investors

• Beyond oncology - Explore how precision medicine is expanding beyond oncology in other therapeutic areas

• On the horizon - A forward-looking perspective on the most exciting developments in precision medicine

How to register?

⬅识别左侧二维码或点击“阅读原文”进行报名

Session Time: Sep 14th, 11:15am-12:15pm EST 

Venue: Stata Center, 32 Vassar St, Cambridge, MA 02139

Speakers Introduction 

Frank Stegmeier，PhD

CSO Partner

@ Curie.Bio

Frank is currently CSO Partner at Curie.Bio, a founder-focused venture firm that invest in early stage companies to help founders turn their ideas into transformative medicines in a capital efficient way. Prior to joining Curie.Bio, Frank was the Chief Scientific Officer at KSQ Therapeutics, a biotech company that that has built an industry-leading CRISPRomics platform to discover optimal oncology and IO targets, where he advanced the first selective USP1 inhibitor and eTIL programs into the clinic.  Prior to joining KSQ Therapeutics, Frank served as Head of Global Oncology Target Discovery at the Novartis Institutes for Biomedical Research (NIBR), where he was responsible for developing the early oncology drug discovery portfolio. Frank earned his Ph.D. in biology from MIT and was a Helen Hay Whitney postdoctoral fellow at Harvard Medical School.

Jeff Kutok，PhD

CSO

@ Ensem Therapeutics

Jeff is a phvsician and scientist and serves as the Chief Scientific Oficer Of ENSEMTherapeutics.He comes to ENSEM with more than 25 years clinical practicetranslational scientific research, and biotech leadership experience in oncology, immuno.oncology,and epigenetics.As anexperienced biotech executive in the drugdevelopment space, Jeff recently served as the Chief Scientific Officer at Epizyme, inc.where he led the company's scientific strategy, including directing preclinical research tosupport the further development of the EZH2 inhibitor, TAZVERIK® (tazemetostat). anoadvancing the company's broader epiaenetic pipeline. He also served as a member ofthe leadership team during its acquisition by lpsen. Prior to joining Epizyme, he servedas Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Incwhere he was responsible for the company's scientific strategy, preclinical developmentand translational science. During his tenure at infinity, the company advanced severaoral Pl3K inhibitors into the clinic. He was also part of the leadership team during theAbbVie partnership and was involved in the licensing of the Pl3K6/y inhibitor.COP|KTRA® (duvelisib) to Verastem Oncology.

Prior to his industry experience, Jeff was an Associate Professor of Pathology at HarvaroMedical School and Brigham and Women's Hospital (BWH) and is board certified inAnatomic Pathology and Hematology. His laboratory at BWH focused on translationamedicine research and biomarker identification in oncology and he is a leading expert incancer biology, with authorship on over 200 journal articles, reviews, and book chaptersJeff received his B.S.in Biology and his M.D., Ph.D.in Medicine and MolecularPathology from Stony Brook University.

Shirley Liu，PhD

co-Founder & CEO

@ GV20 Therapeutics

Dr. X. Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical stage biopharmaceutical company with pioneering technologies in novel target identification and antibody drug discovery in Oncology. Dr. Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. She has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University, until she joined GV20 full-time in 2022. Her research work focused on algorithm development and data integration modeling for translational cancer research. She has published over 270 papers and has an H-index of 120. Dr. Liu is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE) and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Her lab has mentored 27 PhD and postdoctoral trainees to independent academic careers. 

Lihua Yu，PhD

(Host)

Chief Data Officer

@ LifeMine Therapeutics 

As LifeMine’s chief data officer, Lihua brings vast experience in drug discovery from target identification to translational medicine, data science and early clinical development. Lihua is passionate about integrating and applying data science across R&D, partnering with all functions to drive the platform and pipeline forward.

Lihua was previously at FogPharma, where she led the data science function and co-led the company’s discovery platform and new targets. Prior to Fog, Lihua was at H3, where she first served as head of bioinformatics and later as chief data science officer and president. Preceding H3, Lihua was the cancer bioinformatics leader at AstraZeneca Oncology US.

Lihua holds a Ph.D. in biomedical engineering from Boston University, studying under Dr. Temple Smith, and an M.E. and B.E. in biomedical engineering from Tsinghua University in Beijing, China

More about the Conference

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a global biotechnology ecosystem with a collaborative and supportive professional network, promote leadership and entrepreneurship, and facilitate the translation of life science innovations.

Follow us on Twitter: 
https://twitter.com/BioSpark_Group

Follow us on LinkedIn: 
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar: 
https://tinyurl.com/tcwy44t6

Email us: [e-mail]

合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group

更多精彩，请关注BioSpark公众号